EP 3866768 A4 20220105 - USE OF REBOXETINE TO TREAT NARCOLEPSY
Title (en)
USE OF REBOXETINE TO TREAT NARCOLEPSY
Title (de)
VERWENDUNG VON REBOXETIN ZUR BEHANDLUNG VON NARKOLEPSIE
Title (fr)
UTILISATION DE RÉBOXÉTINE POUR TRAITER LA NARCOLEPSIE
Publication
Application
Priority
- US 201862745956 P 20181015
- US 2019056134 W 20191014
Abstract (en)
[origin: WO2020081461A1] Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof. Reboxetine may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
IPC 8 full level
A61K 9/22 (2006.01); A61K 31/5375 (2006.01); A61P 25/00 (2006.01)
CPC (source: EP KR)
A61K 31/5375 (2013.01 - EP KR); A61P 25/00 (2018.01 - EP KR); A61P 25/20 (2018.01 - KR)
Citation (search report)
- [XI] SCHMIDT CHRISTIAN ET AL: "The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram", BEHAVIOURAL BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 308, 23 April 2016 (2016-04-23), pages 205 - 210, XP029542431, ISSN: 0166-4328, DOI: 10.1016/J.BBR.2016.04.033
- [XI] GARCIA-BORREGUERO D ET AL: "Effects of reboxetine in narcolepsy-cataplexy: Preliminary findings on 14 patients", SLEEP (ROCHESTER), vol. 24, no. Abstract Supplement, 15 April 2001 (2001-04-15), & 15TH ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES; CHICAGO, ILLINOIS, USA; JUNE 05-10, 2001, pages A323 - A324, XP009531711, ISSN: 0161-8105
- [XPI] O' GORMAN CEDRIC ET AL: "SCIENTIFIC RATIONALE AND CLINICAL DEVELOPMENT OF AXS-12 FOR NARCOLEPSY", SLEEP, vol. 42, no. Abstract Supplement, 1 January 2019 (2019-01-01), pages A24, XP055866024
- See also references of WO 2020081461A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2020081461 A1 20200423; AU 2019361915 A1 20210513; AU 2023200917 A1 20230323; BR 112021007019 A2 20210713; CA 3115983 A1 20200423; CL 2021000924 A1 20210903; CN 112888430 A 20210601; CO 2021004681 A2 20210621; CR 20210514 A 20211112; EC SP21031200 A 20210531; EP 3866768 A1 20210825; EP 3866768 A4 20220105; IL 282311 A 20210531; JP 2022504975 A 20220113; KR 20210071046 A 20210615; MX 2021004207 A 20210811; PE 20211199 A1 20210701; SG 11202103588W A 20210528
DOCDB simple family (application)
US 2019056134 W 20191014; AU 2019361915 A 20191014; AU 2023200917 A 20230216; BR 112021007019 A 20191014; CA 3115983 A 20191014; CL 2021000924 A 20210414; CN 201980067756 A 20191014; CO 2021004681 A 20210414; CR 20210514 A 20191014; EC DI202131200 A 20210430; EP 19874099 A 20191014; IL 28231121 A 20210413; JP 2021520615 A 20191014; KR 20217013455 A 20191014; MX 2021004207 A 20191014; PE 2021000514 A 20191014; SG 11202103588W A 20191014